Case Study

Biotech Submits NDA After Risk-Based Mock Inspection

GettyImages-1136181171 inspection

An emerging biotech company recently collaborated with inSeption Group to take a preventative approach to mitigate risks, identify potential concerns before an FDA inspection, and submit their NDA. The comprehensive risk-based strategy combined various approaches to ensure a thorough examination of all aspects of clinical studies and Quality Management System.

See how the sponsor was able to address gaps within its application by reading this case study.

access the Case Study!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader